MedPath

Ascletis Pharmaceuticals Co., Ltd.

Ascletis Pharmaceuticals Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

24

Active:2
Completed:21

Trial Phases

3 Phases

Phase 1:13
Phase 2:7
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials

Phase 1
13 (54.2%)
Phase 2
7 (29.2%)
Phase 3
4 (16.7%)

A Study to Evaluate Safety of ASC40 Tablets in Patients with Moderate to Severe Acne Vulgaris

Phase 3
Active, not recruiting
Conditions
Acne
Interventions
First Posted Date
2024-02-08
Last Posted Date
2025-03-12
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
240
Registration Number
NCT06248008
Locations
🇨🇳

Huashan Hospital Fudan University, Shanghai, Shanghai, China

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Phase 3
Completed
Conditions
Acne
Interventions
First Posted Date
2024-01-05
Last Posted Date
2025-06-19
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
480
Registration Number
NCT06192264
Locations
🇨🇳

The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China

🇨🇳

The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China

and more 38 locations

Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
COVID-19
Interventions
Drug: ASC11 tablets
Drug: Placebo
First Posted Date
2023-02-08
Last Posted Date
2024-11-13
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
72
Registration Number
NCT05718518
Locations
🇨🇳

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

Phase 1
Withdrawn
Conditions
SARS CoV 2 Infection
Interventions
Drug: Placebo
First Posted Date
2022-10-27
Last Posted Date
2024-11-01
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
32
Registration Number
NCT05596045
Locations
🇺🇸

Pinnacle Research Group, Anniston, Alabama, United States

🇺🇸

Aga Clinical Trials, Hialeah, Florida, United States

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

Phase 1
Completed
Conditions
SARS CoV 2 Infection
Interventions
Drug: Placebo
First Posted Date
2022-08-31
Last Posted Date
2022-12-16
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
72
Registration Number
NCT05523141
Locations
🇨🇳

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.